Zevra Therapeutics

是其中之一......

• Russell 3000;
• TOB Iconic 10,000.

Zevra Therapeutics 是一家在股票代码 ZVRA (US) 下上市的公司。

他们在：

• 药店50%
• 生物技术50%

查看带有其 40 名主要高管的组织结构图

Zevra Therapeutics 搜索最多的简介

• Neil Mcfarlane, Chief Executive Officer and President
• John Bode, Director
• Thomas Anderson, Director

高管在Zevra Therapeutics变化

• Christal Mickle, Chief Product Development Officer, 已经离开公司  (新闻发布的2024十二月9号).
• Sven Guenther, Chief Scientific Officer, 将于 202412月23 退休  (新闻发布的2024十二月9号).
• Rahsaan Thompson已作为Chief Legal Officer, Secretary and Compliance Officer加入公司  (新闻发布的2024六月26号).

更多的变化在％s

创建提醒
跟踪 Zevra Therapeutics 的高管变动

Zevra Therapeutics 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。

Popular M&A news in 药店

• Cosette Pharmaceuticals has announced the acquisition of Mayne Pharma  (公布2025二月25号).
• Bain Capital 已收购 Mitsubishi Tanabe Pharma (公布2025二月12号).
• Crown Laboratories 已收购 Revance Therapeutics (公布2025二月9号).

药店 行业的其他推荐联系人

• Adare Pharmaceuticals 企业 Kristin Berkinsky - Chief Human Resources Officer
• Amneal Pharmaceuticals 企业 Paul Meister - Chairman of the Board
• Braeburn Pharmaceuticals 企业 Seth Harrison - Chairman and Director

了解更多有关药店行业的信息 >

Zevra Therapeutics 的最新新闻稿

• KemPharm to Report Second Quarter 2022 Financial Results | KemPharm
• KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference | KemPharm
• KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting | KemPharm
• KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion | KemPharm
• Press Releases | KemPharm
• KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline | KemPharm
• KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates | KemPharm
• Press Releases | KemPharm
• KemPharm to Present at Multiple Upcoming Investor Conferences | KemPharm
• KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH) | KemPharm
• View more press releases Close

关于 Zevra Therapeutics 的社交媒体

• Zevra Therapeutics 在 维基百科、谷歌新闻 和 雅虎财经
• Zevra Therapeutics 在 LinkedIn、叽叽喳喳 和 YouTube